Christophe Bourdon

Chief Executive Officer at CytRx Corp.

Christophe Bourdon

Christophe Bourdon

Chief Executive Officer at CytRx Corp.

Biography

Presently, Christophe Bourdon is Chief Executive Officer of Orphazyme A. In his past career Mr. Bourdon was Senior Vice President & General Manager-US Oncology at Amgen, Inc. Mr. Bourdon received an MBA from International Institute for Management Development and an undergraduate degree from Institut Supérieur de Gestion.

Overview
Career Highlights

CytRx Corp.
Orphazyme A/S

RelSci Relationships

1922

Birthday

1970

Age

51

Relationships
RelSci Relationships are individuals Christophe Bourdon likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer, President at Kriegsman Family Office

Relationship likelihood: Strong

Director at CytRx Corp.

Relationship likelihood: Strong

General Partner & Founder at Sunstone Capital A/S

Relationship likelihood: Strong

Founder at LSP Management Group BV

Relationship likelihood: Strong

Managing Partner at Kurma Partners SA

Relationship likelihood: Strong

Venture Partner at Eurazeo Investment Manager - EIM SA

Relationship likelihood: Strong

Former President & Chief Executive Officer at CytRx Corp.

Relationship likelihood: Strong

Co-Founder & CSO at Orphazyme A/S

Relationship likelihood: Strong

Chief Financial Officer, Treasurer & Senior Vice President at CytRx Corp.

Relationship likelihood: Strong

Chief Financial Officer at Orphazyme A/S

Relationship likelihood: Strong

Paths to Christophe Bourdon
Potential Connections via
Relationship Science
You
Christophe Bourdon
Chief Executive Officer at CytRx Corp.
Education

IMD business school is located in Lausanne, Switzerland. It consistently ranks at the top compared to other business schools worldwide. In 2012 and 2013, it was ranked first in open programs worldwide by the Financial Times. Its MBA program is ranked among the top tier programs in the world.

ISG Business School is a school.

Career History
Chief Executive Officer
2021 - Current

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Chief Executive Officer
2021 - Current

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Senior Vice President, General Manager-US Oncology
Prior

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Other Affiliations

Christophe Bourdon is affiliated with CytRx Corp., Orphazyme A/S, Amgen, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Christophe Bourdon. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Christophe Bourdon's profile does not indicate a business or promotional relationship of any kind between RelSci and Christophe Bourdon.